Advanced search
1 file | 1.54 MB

The European Hematology Association Roadmap for European hematology research: a consensus document

(2016) HAEMATOLOGICA. 101(2). p.115-208
Author
Organization
Abstract
The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at (sic)23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine 'sections' in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients.
Keywords
ACUTE MYELOID-LEUKEMIA, STEM-CELL TRANSPLANTATION, CHRONIC LYMPHOCYTIC-LEUKEMIA, THROMBOTIC THROMBOCYTOPENIC PURPURA, PERIPHERAL T-CELL, THROMBOPOIETIN-RECEPTOR AGONISTS, ACUTE LYMPHOBLASTIC-LEUKEMIA, ACUTE PROMYELOCYTIC LEUKEMIA, RANDOMIZED-CONTROLLED-TRIAL, HEMOLYTIC-UREMIC SYNDROME

Downloads

  • 2016 Haematologica European guidelines.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 1.54 MB

Citation

Please use this url to cite or link to this publication:

Chicago
Engert, Andreas, Carlo Balduini, Anneke Brand, Bertrand Coiffier, Catherine Cordonnier, Hartmut Döhner, Thom Duyvené de Wit, et al. 2016. “The European Hematology Association Roadmap for European Hematology Research: a Consensus Document.” Haematologica 101 (2): 115–208.
APA
Engert, A., Balduini, C., Brand, A., Coiffier, B., Cordonnier, C., Döhner, H., Duyvené de Wit, T., et al. (2016). The European Hematology Association Roadmap for European hematology research: a consensus document. HAEMATOLOGICA, 101(2), 115–208.
Vancouver
1.
Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, et al. The European Hematology Association Roadmap for European hematology research: a consensus document. HAEMATOLOGICA. 2016;101(2):115–208.
MLA
Engert, Andreas et al. “The European Hematology Association Roadmap for European Hematology Research: a Consensus Document.” HAEMATOLOGICA 101.2 (2016): 115–208. Print.
@article{8035170,
  abstract     = {The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at (sic)23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. 
The EHA Roadmap identifies nine 'sections' in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. 
The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients.},
  author       = {Engert, Andreas and Balduini, Carlo and Brand, Anneke and Coiffier, Bertrand and Cordonnier, Catherine and Döhner, Hartmut and Duyvené de Wit, Thom and Eichinger, Sabine and Fibbe, Willem and Green, Tony and de Haas, Fleur and Iolascon, Achille and Jaffredo, Thierry and Rodeghiero, Francesco and Salles, Gilles and Schuringa, Jan Jacob and EHA Roadmap for European Hematology Research, the other authors of the and Taghon, Tom},
  issn         = {0390-6078},
  journal      = {HAEMATOLOGICA},
  keywords     = {ACUTE MYELOID-LEUKEMIA,STEM-CELL TRANSPLANTATION,CHRONIC LYMPHOCYTIC-LEUKEMIA,THROMBOTIC THROMBOCYTOPENIC PURPURA,PERIPHERAL T-CELL,THROMBOPOIETIN-RECEPTOR AGONISTS,ACUTE LYMPHOBLASTIC-LEUKEMIA,ACUTE PROMYELOCYTIC LEUKEMIA,RANDOMIZED-CONTROLLED-TRIAL,HEMOLYTIC-UREMIC SYNDROME},
  language     = {eng},
  number       = {2},
  pages        = {115--208},
  title        = {The European Hematology Association Roadmap for European hematology research: a consensus document},
  url          = {http://dx.doi.org/10.3324/haematol.2015.136739},
  volume       = {101},
  year         = {2016},
}

Altmetric
View in Altmetric
Web of Science
Times cited: